The MonarchE trial: improving the clinical outcome in HR+/HER2- early breast cancer: recent results and next steps

被引：4

作者：

Bertucci, Francois ^{[1
,2
,3
]}

Finetti, Pascal ^{[1
]}

Mamessier, Emilie ^{[1
]}

De Nonneville, Alexandre ^{[1
,2
]}

机构：

[1] Aix Marseille Univ, Paoli Calmettes Inst, Canc Res Ctr Marseille, Lab Predict Oncol,INSERM,CNRS,UMR 1068,UMR 725,Tea, Marseille, France

[2] Paoli Calmettes Inst, Dept Med Oncol, Marseille, France

[3] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguer, F-13009 Marseille, France

来源：

CANCER COMMUNICATIONS | 2023年 / 43卷 / 08期

关键词：

PALBOCICLIB;

D O I：

10.1002/cac2.12466

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：938 / 942

页数：5

共 50 条

[1] Abemaciclib for the treatment of HR+/HER2- breast cancer
Exman, Pedro
Tolaney, Sara M.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
[2] Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
Turner, Nicholas
Reis-Filho, Jorge
Goetz, Matthew
Desmedt, Christine
Chandarlapaty, Sarat
Sasano, Hironobu
Arteaga, Carlos
Loi, Sherene
Graff, Stephanie
Liu, Deli
Rodrik-Outmezguine, Vanessa
Sireci, Anthony
Rubenstein, Cynthia Sandoval
Won, Helen
Litchfield, Lacey M.
Munoz, Maria
Johnston, Stephen
CANCER RESEARCH, 2024, 84 (09)
[3] American Society of Clinical Oncology 2021 Podcast: HR+, HER2- Breast Cancer
Cheung, Kwok-Leung
ONCOLOGY AND THERAPY, 2021, 9 (02) : 267 - 272
[4] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston, Stephen R. D.
Harbeck, Nadia
Hegg, Roberto
Toi, Masakazu
Martin, Miguel
Shao, Zhi Min
Zhang, Qing Yuan
Martinez Rodriguez, Jorge Luis
Campone, Mario
Hamilton, Erika
Sohn, Joohyuk
Guarneri, Valentina
Okada, Morihito
Boyle, Frances
Neven, Patrick
Cortes, Javier
Huober, Jens
Wardley, Andrew
Tolaney, Sara M.
Cicin, Irfan
Smith, Ian C.
Frenzel, Martin
Headley, Desiree
Wei, Ran
San Antonio, Belen
Hulstijn, Maarten
Cox, Joanne
O'Shaughnessy, Joyce
Rastogi, Priya
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
[5] Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial
Rubenstein, C. S.
Turner, N.
Reis-Filho, J. S.
Goetz, M. P.
Desmedt, C.
Chandarlapaty, S.
Sasano, H.
Arteaga, C. L.
Loi, S.
Graff, S. L.
Liu, D.
Rodrik-Outmezguine, V.
Sireci, A.
Won, H.
Litchfield, L. M.
Munoz, M.
Johnston, S.
BREAST, 2025, 80
[6] Fulvestrant in clinical practice: Effectiveness analysis in Uruguayan patients with HR+/HER2- breast cancer
Camejo, Natalia
Amarillo, Dahiana
Castillo, Cecilia
Alza, Sofia Badia
Balino, Camila
Banchieri, Miguel
Fagundez, Juan
Ghiga, Santiago
Lorier, Marcos
Alonso, Isabel
Waltier, Gabriel David Krygier
MEDWAVE, 2024, 24 (08):
[7] Sequencing Therapies: Optimal Treatment for HR+/HER2- Metastatic Breast Cancer
Kaklamani, Virginia
Rugo, Hope S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01) : 25 - 27
[8] Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer
Ni, Hua
Kumbrink, Joerg
Mayr, Doris
Seiler, Alina
Hagemann, Friederike
Degenhardt, Tom
Sagebiel, Sabine
Wuerstlein, Rachel
Kates, Ronald
Harbeck, Nadia
Eggersmann, Tanja K.
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
[9] Clinical outcome for HR+/HER2-stage IV breast cancer patients
Goto, Risa
Aruga, Tomoyuki
Honda, Yahoi
Idera, Nami
Horiguchi, Kazumi
Miyamoto, Hiromi
Yamashita, Toshinari
Horiguchi, Shinnichiro
Kuroi, Katsumasa
ANNALS OF ONCOLOGY, 2015, 26 : 142 - 142
[10] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
D. Johnston, Stephen R.
Rugo, Hope S.
Tolaney, Sara M.
Fernandez, Maria Munoz
Wei, Ran
Martin, Miguel
FUTURE ONCOLOGY, 2024, 20 (28) : 2037 - 2048

← 1 2 3 4 5 →